Form AW ONCOLYTICS BIOTECH INC

 

Oncolytics Biotech Inc.

4350 Executive Drive, Suite 325

San Diego, California 92121

 

April 8, 2026

 

Via EDGAR

 

Office of International Corporate Finance

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Re:

Oncolytics Biotech Inc.

Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10

 

To Whom It May Concern:

 

Pursuant to Rule 477(a) of the U.S. Securities Act of 1933, as amended, Oncolytics Biotech Inc. (the “Company”) hereby requests the withdrawal of (i) Post-Effective Amendment No. 1 to each of the Company’s registration statements on Form F-10 (File Nos. 333-140460, 333-140529, 333-151513, 333-167250, 333-182260, 333-197633, 333-224432, 333-239025, 333-265510, and 333-281009) (collectively, the “Registration Statements”), filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) on April 1, 2026 (Accession Nos. 0001104659-26-038088, 0001104659-26-038089, 0001104659-26-038090, 0001104659-26-038091, 0001104659-26-038093, 0001104659-26-038094, 0001104659-26-038095, 0001104659-26-038097, 0001104659-26-038098, and 0001104659-26-038099) and (ii) Post-Effective Amendment No. 2 to each of the Registration Statements, filed by the Company with the Commission on April 6, 2026 (Accession Nos. 0001104659-26-040020, 0001104659-26-040021, 0001104659-26-040022, 0001104659-26-040023, 0001104659-26-040024, 0001104659-26-040025, 0001104659-26-040026, 0001104659-26-040027, 0001104659-26-040028, and 0001104659-26-040029) (together, the “Post-Effective Amendments”).

 

The Company is requesting withdrawal of the Post-Effective Amendments in order to file a replacement post-effective amendment reflecting a revised proposed effective time and date pursuant to Rule 467(b). No securities were sold pursuant to the Post-Effective Amendments.

 

Please direct any questions or comments concerning this request to the Company’s counsel, Latham & Watkins LLP, by calling Christopher J. Clark at (202) 637-2374.

 

	Sincerely,
	ONCOLYTICS BIOTECH INC.
	/s/ Kirk Look
	Kirk Look
	Chief Financial Officer

 

cc:

Jared Kelly, Chief Executive Officer, Oncolytics Biotech Inc.

 

Christopher J. Clark, Latham & Watkins LLP

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ONCY secures U.S. patent for pelareorep manufacturing through 2044
• Infield Minerals Announces Intention to Issue Shares for Kings Canyon Gold Property Option Payment
• Cleveland Market President of First Horizon Bank, Logan Young, Named Manager of Business Banking for East Tennessee Region